Yunkang Group (2325) H1 2023 earnings summary

Executive summary

• H1 revenue fell 65.4% YoY to RMB476.9m as weaker nationwide demand reduced diagnostic testing volumes; profit fell 79.5% to RMB48.0m.

• Strategy centered on deeper customer services and lean operations, expanding diagnostic capabilities, hospital alliances and digital operations.

Financial highlights

• Revenue was RMB476.9m, down 65.4% YoY; gross profit declined 72.1% to RMB181.7m as cost of revenue fell 59.4% to RMB295.2m.

• Profit before tax was RMB50.8m versus RMB283.5m; profit for the period was RMB48.0m versus RMB234.8m, down 79.5% YoY.

• Basic and diluted EPS were RMB0.08 versus RMB0.44; operating profit was RMB65.9m versus RMB287.3m, while net finance costs rose to RMB15.1m from RMB3.8m.

• Other gains, net, were RMB31.1m versus a RMB0.2m loss, including gains from FX and FVTPL asset redemptions; R&D expense rose 3.9% to RMB26.4m.

• Administrative expenses fell 37.4% to RMB80.5m and selling expenses fell 60.3% to RMB86.9m.

Outlook and guidance

• H2 priorities included advancing customer-service systems and lean operations, strengthening regional coverage and improving local service capabilities.

• Plans included expanding medical institution and county-level alliances, regional markets and diagnostic capabilities in oncology, genetics and infectious diseases.

• Digital diagnostic services and laboratory system upgrades were planned over two to three years; potential acquisitions or investments may support operational and technology capabilities.